tofogliflozin hydrate Report issue

Small molecule Experimental
AACT ChEMBL DrugBank Drug Central KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now

Chemistry

  • SMILES: CCc1ccc(Cc2ccc3CO[C@]4(O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)c3c2)cc1
  • InChIKey: VWVKUNOPTJGDOB-BDHVOXNPSA-N
  • Mol. Mass: 386.44
  • ALogP: 1.0
  • ChEMBL Molecules:
    tofogliflozin  
    tofogliflozin  
More Chemistry

Pharmacology

Alternative names

6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3h),2'-(2h)pyran)-3',4',5'-triol | apleway | csg452 | deberza | ro4998452 | tofogliflozin | tofogliflozin anhydrous | tofogliflozin hydrate

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (5)

Approved Indications (1)


 

Diabetes Mellitus, Type 2

Experimental Indications - Clinical Trial Phases 1-4 (5)


 

Diabetes Mellitus, Type 2 (Phase 4)

Healthy Volunteers (Phase 1)

Metformin (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 4)

Sodium-Glucose Transporter 2 Inhibitors (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue